México, November 13, 2009

MENINGITIS MANAGEMENT COSTS IN MEXICO PART I:

Expert panel on the utilization of resources for a case of meningococcal

meningitis

PART II:Information obtained from patient files

COST OF HANDLING MENINGITIS IN MEXICO PART I:

Results from a Delphi Panel: Utilization of resources for a case of meningococcal meningitis

3

BACKGROUND

MENINGOCOCCAL INVASIVE DISEASE

Meningitis and bacterial sepsis are the inflammatory response of the leptomeninges cells and the subarachnoid space against aggressions of diverse nature such as: infectious, chemical (contrast, medication), tumorous (carcinomatose meningitis) or autoimmune (vasculitis).

Worldwide incidences and prevalence are unknown; however, we do know that 70 percent of cases occur in children under 5 years of age. 75-80 percent of meningitis occurring out of the neonatal period is produced by three pathogens: meningococcus, pneumococcus and Haemophilus influenzae. For this reason they are considered critical diseases that endanger the child’s life, or can leave irreversible sequelae.

BACKGROUND

MENINGOCOCCAL INVASIVE DISEASE

Meningitis and bacterial sepsis etiology in our environment have experienced important epidemiological changes in the last years. The incidence of etiological agents is basically influenced by external factors of sanitary policy.

Bacterial origin meningitis, caused mainly by Neisseriae meningitidis and Streptococcus pneumoniae, represent the most lethal form of the disease, and its distribution, morbidity and mortality are determined by the social and economic conditions of the poorest communities and countries in the World, where preventive vaccination and medication for its control are very limited by the levels of economic development.

4

5

OBJECTIVE

To identify resources utilization pattern for a case of bacterial menigococcal meningitis within the Mexican health sector.

METHODS AND MATERIALS

DELPHI PANEL

The study was carried out by adapting Delphi methodology, in order to identify participant's response patterns through a series of sequenced questionnaires.

Some characteristics of this methodology (Delphi) include a very high minimization of influence between participants, equal opportunities for participation and a good performance with heterogeneous groups.

Verbal communication skills are not required, and even though they don’t guarantee representation of participants, written communication skills are necessary.

6

7

METHODS AND MATERIALS

DELPHI PANEL (continued)

During the first stage, a questionnaire was used as a starting point for specialists to express their individual estimations. Then, the questionnaires were collected and the responses were statistically analyzed and integrated into a second questionnaire. In this stage, specialists evaluate the previously obtained responses to indicate agreement or disagreement with them and corroborate or rectify the primary responses.

Just as other methods of consensus, the Delphi is proposed for problems that need to be investigated quickly and inexpensively. Its alteration depends on the area of interest and context where it's being applied, which is why variations in practice are justified.

8

METHODS AND MATERIALS

DELPHI PANEL (continued)

This analysis made use of the Delphi method in order to identify a resource utilization pattern for treatment of bacterial meningitis by meningococcus. The end result was to conduct a study of cost associated with this malady.

The study was conducted between august and october 2009

through the use of 2 questionnaires and two rounds of consultations.

METHODS AND MATERIALS

The following flow chart details the process that was followed.

9

Source: Polytechnic University of Madrid http://www.gtic.ssr.upm.es/encuestas/delphi.htm

METHODS AND MATERIALS

PARTICIPANTS

Five infectology and pediatric infectology specialists belonging to highly specialized hospitals from the public and private sector. Participant selection was carefully controlled with criteria ranging from gender, age, research activities, position in their respective hospitals and experience in treating the disease.

EXCLUSION CRITERIA

Non-infectology specialists, infectology specialists with an administrative position at the time that the evaluation was conducted.

10

METHODS AND MATERIALS

INSTRUMENTS

A questionnaire was designed and delivered to the participants via electronic format. It mainly dealt with resource utilization for the treatment of meningococcal meningitis.

Central tendency measures were obtained from the first stage of responses. The second, or validation, stage, was developed the following month. In this stage, participants were required to ratify or modify their original response.

The questionnaire, made up of fifty-two items, evaluated two sections: Acute Phase and Management of Sequelae.

11

12

METHODS AND MATERIALS

ACUTE PHASE

First contact and follow-up

Hospitalization

Number of cases attended to in clinical practice

Laboratory studies

Cabinet studies

Invasive medical procedures

Pharmacological treatment

Blood transfusion and hemoderivatives

Relatives that were recommended for prophylaxis and medicine

13

METHODS AND MATERIALS

SEQUELAE MANAGEMENT

Types of sequelae and patient percentage

Appointment follow-up (twelve month period by types of sequelae)

Laboratory studies (twelve month period by types of sequelae)

Cabinet studies (twelve month period by types of sequelae)

Medical devices by sequelae

Pharmacological treatment (twelve month period by types of sequelae)

Patient survival (percentage)

Impact on quality of life (percentage)

Amputation costs

14

ANALYSIS AND RESULTS

DATA

The study was conducted in order to find out resource utilization when treating a typical or average case of a patient with bacterial meningitis by meningococcal.

The following results were obtained by a second questionnaire (validation); they were statistically processed and provided central tendency measures.

Results analysis and diagram presentation used the median, as it is less sensitive to variable oscillation values than the mean, therefore not affected by dispersion.

15

ANALYSIS AND RESULTS

MAIN FINDINGS

Average meningitis meningococcus cases that specialists have worked with: 7

Average of hospital stay, caused by meningococcal meningitis: 16 Percentage of patients that retain sequelae after disease was

presented: 50%. Survival percentage: 70%. Epilepsy, amputations, and mild hypoacusia are the most prevalent

sequelae, after the disease presents itself. Given the sequelae, rehabilitation appointments are a top priority for

patients that presented meningococcemia profiles. Cost of minor amputation: 20 thousand mexican pesos; Cost of major

amputation: 50 thousand mexican pesos. No information on medication use was found, even when this category

was explicitly researched.

ANALYSIS AND RESULTS

16

MAIN RESULTS

Type and number of consultations that intervened in a case of meningococcemia

Acute Phase1st Contact and Monitoring

Number of Specialty Consultations

1 1 1 13 4 4.5

22

Neurology

Pediatrics or in

ternal medicine

Intensive care

Emergency

Neurosurgery

Consultation with Specialist (total)

Infectology

Rehabilitation

MAIN RESULTS

Average of hospital stay (days), caused by a case of meningococcal meningitis

17

Acute PhaseAverage Hospital Stay

1

7

8

Emergency ICU Hospital f loor

ANALYSIS AND RESULTS

ANALYSIS AND RESULTS

18

MAIN

RESULTS

Number of Laboratory Studies that intervene with treating a case of

meningitis by meningococcus.

Acute PhaseLaboratory Test

0.5 0.51

1.5 1.52 2

2.5 2.5 2.5 2.75 3 3 3 3 33.5 3.53.75

7

8

11

6.5

54.54.5

44444

ANALYSIS AND RESULTS

MAIN RESULTS

Number of Cabinet Studies used for treating a case of meningococcal meningitis

19

Acute PhaseCabinet Studies

1 1 11.5

2 2 22.5

9

Ultr

ason

ogra

phy

MR

IEc

hoca

rdio

gram

s

CT

scan

EEG

BAER VE

PEl

ectro

card

iogr

ams

X-R

ays

ANALYSIS AND RESULTS

MAIN RESULTS

Invasive medical procedures used for treating a case of meningococcal meningitis

20

Acute PhaseInvasive Medical Procedures

2.5

4.55

10.25

Lumbar punctures Endotracheal intubation(no. of days)

Arterioclisis (no. of days) Central catheters (no. ofdays)

ANALYSIS AND RESULTS

MAIN RESULTS

Blood transfusions and hemoderivatives for treatment of meningitis meningococcal

21

Acute PhaseBlood transfusions and hemoderivatives

22.25

4.5

6

Gamma globulins Globular packages FFP Platelet count

ANALYSIS AND RESULTS

MAIN RESULTS

Percentage of sequelae by meningitis meningococcal

22

Sequelae ManagementSequelae (% of patients)

2% 4% 8%

8%

8%

8%

9%9%14%

30%

Loss of visual acuity

Sore / Grafts

Severe hearing loss

Mental retardation

Sensory-motor deficit

Hydrocephalus

Mediated hearing loss

Amputations

Epilepsy

No sequelae

ANALYSIS AND RESULTS

MAIN RESULTS

Amputation costs (Mexican $)

23

Sequelae ManagementAmputation Costs

$20,000

$50,000

Minor amputation

Major amputation

ANALYSIS AND RESULTS

24

Cost per expert physician survey (Mexican $). 1st Round (Only medical attention costs are included)Cost Source: DOF(Official Government Newspaper)16 April 2007 updated for 2009

Item/ Physician Specialist

1 Specialist

2 Specialist

3 Specialist

4 Specialist

5 General medicine 1 Emergency room 2nd level 1 3rd level 1 Specialty 2nd level 32 3rd level 4 4 25 Hospitalization Days Hospitalized 2nd level 9 3rd level 11 8 5 11 Days in ICU 5 7 5 8 10 Clinical Analyses Applied 76 64 8 86 224 Radiodiagnostic 10 4 8 10 CAT 1 1 3 5 NMR 1 2 2 Electrodiagnostic 4 2 5 12 Ultrasonography 2 1 13 Costs Consultation Costs $2,184 $5,260 $5,260 $1,105 $32,875 Hospitalization Cost $192,844 $234,691 $164,230 $267,537 $333,229 Cost for applied analyses $20,902 $26,168 $736 $56,467 $93,408 Total $215,930 $266,119 $170,226 $325,109 $459,512

ANALYSIS AND RESULTS

25

Cost per expert physician survey (Mexican$). Consensus (only medical attention costs are included)Cost Source DOF 16 April 2007 updated to 2009

Item Consensus General medicine Emergency room 2nd level 1 3rd level Specialty 2nd level 3rd level 15 Hospitalization Days Hospitalized 2nd level 3rd level 8 Days in ICU 7 Clinical Analyses Applied 112 Radiodiagnostic 9 CAT 2 NMR 1 Electrodiagnostic 7 Ultrasonography 1 Costs Consultation Costs $20,830 Hospitalization Cost $234,691 Cost for applied analyses $42,149 Total $297,670

MENINGITIS TREATMENT COSTS IN MEXICOPART II:

Hospital Files Evaluated

ANALYSIS AND RESULTS: Cost of Meningococcal Meningitis

27

Costs from medical files:2 patients detected with meningococcal meningitis: 1 at the “Hospital de Infectología CMN La Raza del IMSS” and 1 in the Private Sector (For this one, cost estimations were made through a public sector tabulator) Cost source: DOF 16 April 2007 updated to 2009

Patient with Meningococcal Meningitis

Item Public Sector

Private Sector

General medicine Emergency room 2nd level 3 3rd level 1 Specialty 2nd level 3rd level 42 3 Hospitalization Days Hospitalized 2nd level 3rd level 6 Days in ICU 10 1 Clinical Analyses Applied 4 35 Radiodiagnostic 1 3 CAT NMR Electrodiagnostic 2 Ultrasonography Costs Consultation Costs $58,545.00 $5,612 Hospitalization Cost $309,384.00 $28,077 Cost for applied analyses $738.00 $4,820 Cost for pharmacological treatment $496.31

Total $369,163.31 $38,509

ANALYSIS AND RESULTS: Cost of Bacterial Meningitis (not meningococcus)

28

Cost (Mexican $) from patient files. (6 patients detected in the “Hospital de Infectología- CMN La Raza del IMSS” )-Cost source:DOF 16 April 2007 updated to 2009

Item/ Patient Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6

General medicine 1 2 Emergency room 2nd level 1 1 1 3rd level 1 2 1 Specialty 2nd level 1 3rd level 3 2 4 7 Hospitalization Days Hospitalized 2nd level 13 3rd level 17 10 45 1 Days in ICU 8 7 9 9 8 30 Clinical Analyses Applied 16 125 98 24 18 11 Radiodiagnostic 2 1 2 2 CAT 1 1 5 1 NMR 1 0 Electrodiagnostic 1 1 2 Ultrasonography 1 1 Costs Consultation Costs $6,129.00 $0.00 $5,964.00 $1,105.00 $7,399.00 $11,977.00 Hospitalization Cost $305,689.00 $306,226.00 $252,693.00 $252,693.00 $439,221.00 $847,079.00 Cost for applied analyses $10,702.00 $29,810.00 $9,261.00 $3,318.00 $44,351.00 $11,102.00 Cost for pharmacological treatment $5,087.61 $1,550.90 $4,310.54 $33,491.19 $40,716.33 $3,544.74 Total $327,607.61 $337,586.90 $272,228.54 $290,607.19 $531,687.33 $873,702.74

29